阿卡波糖联合瑞格列奈治疗2型糖尿病临床观察

Clinical observation on acarbose and acarbose combined with repaglinide in treatment of type 2 diabetes

目的观察阿卡波糖和阿卡波糖联合瑞格列奈治疗2型糖尿病的临床疗效及安全性。方法将48例2型糖尿病患者分2组,分别服用阿卡波糖和瑞格列奈联用阿卡波糖,疗程8周。检测治疗前后空腹(FBG)及餐后2h血糖(PBG)、糖化血红蛋白(HbAlc)、肝功、肾功。结果阿卡波糖组PBG治疗前后差异有统计学意义(P<0.05)。阿卡波糖联合瑞格列奈组FBG、PBG、HbAlc治疗前后差异有统计学意义(P<0.05)。无1例发生严重不良反应。结论阿卡波糖和瑞格列奈联合阿卡波糖治疗2型糖尿病降糖作用确切,而且安全性、耐受性良好。

Objective To evaluate the therapeutic effect and safety of acarbose and aearbose combined with repaglinide in treatment of type 2 diabetes. Methods A total of 48 patients with type 2 diabetes were divided into two groups that took acarbose alone or acarbose combined with repaglinide, respectively, for 8 weeks. Fasting blood glucc,se （FBG）, postprandial blood glucose （PBG）, glycosylated hemoglobin （HbAlc）, and liver and kidney functions were monitored. Results PBG was significantly decreased after the treatment and there was a significant difference in the aearbose group （P〈0.05）. There were significant differences in FBCJ, PBG, and HbAlc before and after the treatment （improvement） in the acarbose combined with repaglinide group. （ P 〈 0.05 ）. No patient had serious reaction. Conclusions Repaglinide and aearbose have the precise function in the treatment of type 2 diabetes, with a good security and good tolerance.